Immunogenicity for Biopharmaceuticals & Biosimilars Asia 2012
|Event Date/Time: Oct 15, 2012||End Date/Time: Oct 17, 2012|
|Early Registration Date: Aug 03, 2012|
â€œGovernments in Asia like Korea and Singapore,
have identified biopharmaceuticals as one of
the future engines for economic growthâ€
- ensure success in the design and commercialization of your biotherapies understanding, predicting and minimizing
the risk of immunogenic responses.
This comprehensive programme will provide you with a detailed insight to the immunogenicity field, including the underlying causes and implications of immunogenicity, current international developments and best practices in immunogenicity risk assessment, prediction, assay development and regulatory expectations and particular considerations for immunogenicity in the Asian region.
5 Reasons to Attend Asia Immunogenicity 2012:
The ONLY event of its kind in Asia - A â€˜must attendâ€™ event given the rapid development of the biotech industry in Asia
The regionâ€™s first to market event highlighting strategies for immunogenicity testing and critical advice to predict and manage unwanted immunogenicity
Immunogenicity is a major bottleneck in the discovery and development of biotherapeutics â€“ Donâ€™t miss this first event in Asia that will provide you with strategies to predict and manage the immunogenicity response
Bringing together a multidisciplinary audience this event will provide strategies from preclinical through to clinical to understand, predict and minimize the risk of an immunogenic response
Regulatory guidances for immunogenicity are unclear â€“ Donâ€™t miss your opportunity to hear a regulatory perspective about minimum data requirements for FDA/EU approval